Prostate Cell News Volume 10.06 | Feb 22 2019

TOP STORY

Neurotensin and Its Receptors Mediate Neuroendocrine Transdifferentiation in Prostate Cancer

Investigators explored and characterized the functional role of neurotensin in cell line and animal models of castration-resistant prostate cancer with neuroendocrine differentiation. [Oncogene] Full Article

(Ranked by impact factor of the journal)

Protein Kinase N1 Control of Androgen-Responsive Serum Response Factor Action Provides Rationale for Novel Prostate Cancer Treatment Strategy

Scientists explored targeting the mechanism by which androgen receptor, via RhoA, conveys androgen-responsiveness to serum response factor, which controls aggressive prostate cancer (CaP) behavior and is maintained in castration-recurrent-CaP. [Oncogene] Abstract

Identification and Characterization of Small Molecule Inhibitors of the Ubiquitin Ligases Siah1/2 in Melanoma and Prostate Cancer Cells

Inhibitors were assessed for their effect on viability of melanoma and prostate cancer cultures, colony formation, prolyl-hydroxylase-HIF1α signaling, expression of selected Siah2-related transcripts, and Siah2 ubiquitin ligase activity. [Cancer Lett] Abstract

KIFC1 Inhibitor CW069 Induces Apoptosis and Reverses Resistance to Docetaxel in Prostate Cancer

The authors assessed the involvement of kinesin family member C1 (KIFC1) in docetaxel (DTX) resistance in prostate cancer (PCa) and examined the effect of KIFC1 on DTX resistance. They also analyzed the possible role of a KIFC1 inhibitor (CW069) in PCa. [J Clin Med] Full Article

Dihydroartemisinin Inhibits Prostate Cancer via JARID2/miR-7/miR-34a-Dependent Downregulation of Axl

Researchers evaluated a library of natural compounds for inhibitors of Axl and identified dihydroartemisinin, the active principle of the anti-malarial drug artemisinin, as an Axl-inhibitor in prostate cancer. Dihydroartemisinin blocked Axl expression leading to apoptosis, decrease in cell proliferation, migration, and tumor development of prostate cancer cells. [Oncogenesis] Full Article

MicroRNA‐200a Suppresses Prostate Cancer Progression through BRD4/AR Signaling Pathway

In vitro studies showed that miR‐200a overexpression in castration‐resistant prostate cancer cells markedly suppressed cellular proliferation and facilitated apoptosis. In vivo studies indicated that overexpression of miR‐200a inhibited growth and metastasis of prostate cancer. [Cancer Med] Full Article

Sinomenine Inhibits Proliferation, Migration, Invasion and Promotes Apoptosis of Prostate Cancer Cells by Regulation of miR-23a

Sinomenine significantly suppressed cell proliferation, promoted apoptosis and inhibited migration and invasion, as well as down-regulated Cyclin D1, CDK4, Bcl-2, MMP-2, MMP-9, Vimentin protein levels and up-regulated p16 and Bax protein levels in PC3 cells. [Biomed Pharmacother] Full Article

Abiraterone Acetate Exerts a Cytotoxic Effect in Human Prostate Cancer Cell Lines

The authors studied the capability of the CYP17A1 inhibitor abiraterone acetate (AER) to antagonize the androgen receptor (AR) activation in human prostate cancer (PCa) cell lines. T877A-AR-LNCaP, WT-AR-VCaP, AR-negative DU145, and PC3 PCa cell lines were used by MTT and cell count to study the ability of AER and enzalutamide to modify cell viability. [Naunyn Schmiedebergs Arch Pharmacol] Abstract

Epithelial-to-Mesenchymal Transition Markers and CD44 Isoforms Are Differently Expressed in 2D and 3D Cell Cultures of Prostate Cancer Cells

Researchers investigated the effect of the 3D arrangement on the expression of some key markers of epithelial-to-mesenchymal transition in cultured human prostate cancer (PCa) cells, to better understand PCa cell behavior. PC3 and DU145 PCa cells were cultured in RPMI cell culture medium either in 2D-monolayers or in 3D-spheroids. [Cells] Full Article

Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News.

PAK4 Signaling in Health and Disease: Defining the PAK4-CREB Axis

The authors review the p21-Activated kinase 4 (PAK4) signaling pathways involved in prostate cancer, Parkinson’s disease, and melanogenesis, focusing in particular on the PAK4-CREB axis. [Exp Mol Med] Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Foresee Pharmaceuticals Announces Successful Topline Results from Phase III Registration Study of LMIS 25 mg in Prostate Cancer

Foresee Pharmaceuticals Co., Ltd. announced the topline results of FP-001 LMIS (Leuprolide Mesylate Injectable Suspension) 25 mg Phase III clinical trial, an open-label, single-arm study in subjects with prostate carcinoma. [Foresee Pharmaceuticals Co., Ltd. (PR Newswire Association LLC.)] Press Release

Nearly $20 Million Awarded by CPRIT to MD Anderson

The University of Texas MD Anderson Cancer Center was awarded $19.6 million from the Cancer Prevention and Research Institute of Texas (CPRIT) to support research, recruitment and prevention efforts. In total, MD Anderson and its projects received 20 percent of the $96 million in awards announced by CPRIT. [The University of Texas MD Anderson Cancer Center] Press Release

Moldovan Mathematician among Academics Running in General Election

Several researchers, including one mathematician, are running for seats in Moldova’s parliament this month. They hope to depoliticize science, improve education and address high levels of brain drain in the small country of 3.5 million people. [Nature News] Editorial

Open-Access Pioneer Randy Schekman on Plan S and Disrupting Scientific Publishing

Nobel laureate Randy Schekman shook up the publishing industry when he launched the open-access journal eLife in 2012. Armed with millions in funding from three of the world’s largest private biomedical charities — the Wellcome Trust, the Max Planck Society and the Howard Hughes Medical Institute — Schekman designed the journal to compete with publishing powerhouses such as Nature, Science and Cell. [Nature News] Editorial

Foreign Governments Want to Boost Their Biotech Industries — So They’re Setting Up Shop in Boston

Cities and states around the corner and around the country have angled for years to set themselves up as the next Kendall Square, hoping to import some of the magic of Boston’s biotech hub and its job-creating economic engine. Increasingly, foreign governments are pushing for the same. [STAT News] Editorial

NEW Keystone Symposia: Cancer Stem Cells – Advances in Biology and Clinical Translation
October 13-17, 2019
Hong Kong, China

Visit our events page to see a complete list of events in the community.

NEW Faculty Position – Prostate Cancer Biology and Cancer Epigenetics (Northwestern University Feinberg School of Medicine)

NEW Advanced Research Assistant – Cellular Generation and Phenotyping (Wellcome Sanger Institute)

Research Assistant II – Cancer Biology (MD Anderson Cancer Center)

Senior Computational Biologist – Molecular Oncology (Cancer Research UK Manchester Institute)

Postdoctoral Positions – Stem Cell and Cancer Biology (Columbia University Irving Medical Center)

Postdoctoral Fellow – Cancer Biology (Thomas Jefferson University)

Assistant Professor – Translational Cancer Research (Texas Tech University Health Sciences Center El Paso)

Postdoctoral Position – Prostate Cancer (University of Trento)

Postdoctoral Fellow – Prostate Cancer & Stem Cell Biology (City of Hope)

Postdoctoral Fellow – Cancer Immunotherapy (University of Notre Dame)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.